TABLE 1.

Summary of TEAEs after a single administration of vutiglabridin

System organ class, Preferred term	Vutiglabridin, 30 mg (N = 8)	Vutiglabridin, 60 mg (N = 8)	Vutiglabridin, 120 mg (N = 8)	Vutiglabridin, 240 mg (fasted) (N = 8)	Vutiglabridin, 240 mg (fed) (N = 8)	Vutiglabridin, 480 mg (N = 8)	Vutiglabridin, 720 mg (N = 8)	Placebo, (N = 12)
TEAEs	1 (12.5)	3 (37.5)	2 (25.0)	1 (12.5)	0 (0.0)	0 (0.0)	1 (12.5)	2 (16.7)
Gastrointestinal disorders		1 (12.5)	1 (12.5)
Gingival pain		1 (12.5)
Stomatitis			1 (12.5)
General disorders and administration site conditions	1 (12.5)
Pyrexia	1 (12.5)
Infections and infestations				1 (12.5)
Upper respiratory tract infection				1 (12.5)
Injury, poisoning and procedural complications							1 (12.5)
Contusion							1 (12.5)
Ligament sprain							1 (12.5)
Musculoskeletal and connective tissue disorders								1 (8.3)
Neck pain								1 (8.3)
Nervous system disorders		2 (25.0)						1 (8.3)
Dizziness		1 (12.5)
Dizziness postural								1 (8.3)
Headache		1 (12.5)
Respiratory, thoracic and mediastinal disorders			1 (12.5)
Rhinorrhea			1 (12.5)

Note: Data are shown as the number of subjects (percentage of subjects).

Abbreviation: TEAE, treatment‐emergent adverse event.